Streetbeat News

Price Targets

COCP

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Cocrystal Pharma (NASDAQ:COCP) and maintained a $12 price target.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 11:09 am

IDYA

Oppenheimer analyst Matthew Biegler has maintained an Outperform rating on IDEAYA Biosciences (NASDAQ:IDYA) and raised the price target from $30 to $35.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 11:08 am

CYBR

Wolfe Research analyst Joshua Tilton has maintained an 'Outperform' rating on CyberArk Software (NASDAQ:CYBR) and raised the price target from $165 to $175.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 11:07 am

ETON

HC Wainwright & Co. analyst Raghuram Selvaraju maintains a 'Buy' rating on Eton Pharmaceuticals (NASDAQ:ETON) and raises the price target from $9 to $10.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 11:06 am

DOCS

Wells Fargo analyst Stan Berenshteyn maintains an Equal-Weight rating on Doximity (NYSE:DOCS) and lowers the price target from $37 to $25.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 11:05 am

BKKT

Rosenblatt analyst Andrew Bond has reiterated a 'Buy' rating on Bakkt Holdings (NYSE:BKKT) and maintained a price target of $2.1.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 11:05 am

OUST

Rosenblatt analyst Kevin Cassidy has reiterated a 'Buy' rating on Ouster (NYSE:OUST) and maintained a price target of $17.5.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 11:02 am

CYBR

Rosenblatt analyst Catharine Trebnick maintains a 'Buy' rating on CyberArk Software (NASDAQ:CYBR) and raises the price target from $185 to $195.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 11:01 am

VIAV

Rosenblatt analyst Mike Genovese has maintained a 'Buy' rating on Viavi Solutions (NASDAQ:VIAV) and raised the price target from $13 to $14.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 11:00 am

OBIO

Chardan Capital analyst Keay Nakae has reiterated a 'Buy' rating on Orchestra BioMed Holdings (NASDAQ:OBIO) and maintained a price target of $20.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 11:00 am